Cassava Sciences Inc. traded at $1.77 this Thursday March 26th, decreasing $0.06 or 3.28 percent since the previous trading session. Looking back, over the last four weeks, Cassava Sciences lost 22.37 percent. Over the last 12 months, its price rose by 4.12 percent. Looking ahead, we forecast Cassava Sciences Inc. to be priced at 1.78 by the end of this quarter and at 1.62 in one year, according to Trading Economics global macro models projections and analysts expectations.
Cassava Sciences, Inc. is a clinical-stage biotechnology company. The Company is focused on developing the drug for the treatment of neurodegenerative diseases, such as Alzheimers disease. The Company’s products include Simufilam and SavaDx. Its lead therapeutic product candidate, Simufilam, is a proprietary small molecule (oral) drug. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimers brain. The SavaDx, is an early-stage program focused on detecting the presence of Alzheimers disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is also developing SavaDx is a quantitative blood-based investigational biomarker/diagnostic to detect and monitor Alzheimer's disease. The Company’s scientific approach for the treatment of Alzheimers disease seeks to simultaneously progress both neurodegeneration and neuroinflammation.